Speaker: Christopher M McGraw, MD, PhD; Assistant Professor, Neurology (Epilepsy/Clinical Neurophysiology), Pharmacology.
Lecture title: Refractory status epilepticus as a model for novel anti-seizure target discovery
Abstract: Status epilepticus (SE) is a life-threatening neurological emergency affecting ~150k people annually in the US, which is characterized by prolonged seizures, often resistant to anti-seizure medications (ASMs) including first line benzodiazepines (BZDs). There is an urgent need for novel therapies to terminate refractory SE. While rodent models have advanced our understanding and treatment of SE in humans, they are costly and logistically intensive for discovering and testing novel therapies at scale. The complex cellular, synaptic, inflammatory, and neurochemical interplay arising during BZD-resistant SE is also unlikely to be fully recapitulated by in vitro or ex vivo models. This seminar will discuss efforts to develop a zebrafish model of refractory status epilepticus and its use for novel anti-seizure target discovery.
Pharmacology Dept
(312) 503-4892
Email